Carter, Sarah P. DiMauro, Jennifer Renshaw, Keith D. Curby, Timothy W. Babson, Kimberly A. and Bonn-Miller, Marcel O. 2016. Longitudinal associations of friend-based social support and PTSD symptomatology during a cannabis cessation attempt. Journal of Anxiety Disorders, Vol. 38, p. 62.
Gouzoulis-Mayfrank, Euphrosyne 2016. Psychotische Störungen und komorbide Suchterkrankungen. Forensische Psychiatrie, Psychologie, Kriminologie, Vol. 10, Issue. 1, p. 14.
Ksir, Charles and Hart, Carl L 2016. Correlation still does not imply causation. The Lancet Psychiatry, Vol. 3, Issue. 5, p. 401.
Ksir, Charles and Hart, Carl L. 2016. Cannabis and Psychosis: a Critical Overview of the Relationship. Current Psychiatry Reports, Vol. 18, Issue. 2,
Rebgetz, Shane Kavanagh, David J. and Hides, Leanne 2016. Changes in cannabis use among psychotic clients without specialised substance use treatment. Schizophrenia Research, Vol. 175, Issue. 1-3, p. 136.
Toftdahl, Nanna Gilliam Nordentoft, Merete and Hjorthøj, Carsten 2016. The Effect of Changes in Cannabis Exposure on Psychotic Symptoms in Patients With Comorbid Cannabis Use Disorder. Journal of Dual Diagnosis, Vol. 12, Issue. 2, p. 129.
Cooper, Katy Chatters, Robin Kaltenthaler, Eva and Wong, Ruth 2015. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technology Assessment, Vol. 19, Issue. 56, p. 1.
Marshall, Max Barrowclough, Christine Drake, Richard Husain, Nusrat Lobban, Fiona Lovell, Karina Wearden, Alison Bradshaw, Tim Day, Christine Fitzsimmons, Mike Pedley, Rebecca Piccuci, Ruth Picken, Alicia Larkin, Warren Tomenson, Barbara Warburton, Jeff and Gregg, Lynsey 2015. The HELPER programme: HEalthy Living and Prevention of Early Relapse – three exploratory randomised controlled trials of phase-specific interventions in first-episode psychosis. Programme Grants for Applied Research, Vol. 3, Issue. 2, p. 1.
Monney, Grégoire Penzenstadler, Louise Dupraz, Olivia Etter, Jean-François and Khazaal, Yasser 2015. mHealth App for Cannabis Users: Satisfaction and Perceived Usefulness. Frontiers in Psychiatry, Vol. 6,
Schultz, Brian R. Rodriguez-Cabezas, Lisette Angres, Dan and Smith, Matthew J. 2015. Treatment Strategies for Cannabis Use in Schizophrenia. Current Treatment Options in Psychiatry, Vol. 2, Issue. 2, p. 168.
Velthorst, E. Koeter, M. van der Gaag, M. Nieman, D. H. Fett, A.-K. J. Smit, F. Staring, A. B. P. Meijer, C. and de Haan, L. 2015. Adapted cognitive–behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychological Medicine, Vol. 45, Issue. 03, p. 453.
Bradizza, Clara M. Stasiewicz, Paul R. and Dermen, Kurt H. 2014. Behavioral Interventions for Individuals Dually Diagnosed with a Severe Mental Illness and a Substance Use Disorder. Current Addiction Reports, Vol. 1, Issue. 4, p. 243.
McLoughlin, Benjamin C Pushpa-Rajah, Jonathan A Gillies, Donna Rathbone, John Variend, Hannele Kalakouti, Eliana Kyprianou, Katerina and McLoughlin, Benjamin C 2014. Cochrane Database of Systematic Reviews.
Hjorthøj, Carsten Rygaard Orlovska, Sonja Fohlmann, Allan and Nordentoft, Merete 2013. Psychiatric treatment following participation in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis. Schizophrenia Research, Vol. 151, Issue. 1-3, p. 191.
Hunt, Glenn E Siegfried, Nandi Morley, Kirsten Sitharthan, Thiagarajan Cleary, Michelle and Hunt, Glenn E 2013. Cochrane Database of Systematic Reviews.
Cannabis abuse in psychotic patients is associated with rehospitalizations, reduced adherence and increased symptom severity. Previous psychosocial interventions have been ineffective in cannabis use, possibly because of low sample sizes and short interventions. We investigated whether adding CapOpus to treatment as usual (TAU) reduces cannabis use in patients with cannabis use disorder and psychosis.
A total of 103 patients with psychosis and cannabis use disorder were centrally randomized to 6 months of CapOpus plus TAU (n = 52) or TAU (n = 51). CapOpus consisted mainly of motivational interviewing and cognitive behaviour therapy (CBT). TAU was targeted primarily at the psychotic disorder. The primary outcome was self-reported days with cannabis use in the preceding month.
Pre-randomization cannabis use frequency was 14.9 [95% confidence interval (CI) 12.7–17.1] days/month. Post-treatment, the ratio of days/month with cannabis use in CapOpus versus TAU was 0.76 (95% CI 0.38–1.50) (p = 0.42), and 0.80 (95% CI 0.21–3.10) (p = 0.75) at the 4-month follow-up. From 46.4 (95% CI 36.4–56.3) monthly joints pre-randomization, consumption fell to 27.3 (95% CI 12.6–41.9) joints in CapOpus and 48.2 (95% CI 31.8–64.6) in TAU (p = 0.06). Follow-up amounts were 28.4 (95% CI 13.5–43.2) and 41.6 (95% CI 25.2–58.0) joints (p = 0.23). Several subgroup analyses suggested benefits of CapOpus.
CapOpus did not reduce the frequency, but possibly the amount, of cannabis use. This is similar to the findings of previous trials in this population. Implementation of CapOpus-type interventions is thus not warranted at present but subgroup analyses call for further trials.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.